Jennie Wilde, Carver Wilde Communications
t: +44 (0) 7799 412230/ +44 (0)203 814 8445
FOR IMMEDIATE RELEASE
Biotech innovator Abviris appoints new leader to drive business expansion
Diagnostics industry expert Dr Roman Niedbal joins as CEO
AHRENSBURG, Germany (December 16, 2020) –Abviris Deutschland GmbH has appointed Dr. Roman Niedbal as its new CEO to spearhead the further development and expansion of the company’s point-of-care solutions. Together with CFO Sven Klose, he will lead a new business development team actively seeking global strategic partners to open up the diagnostic potential of the pioneering Abviris technology.
Dr Niedbal, who holds a doctorate in microbiology, was previously Vice President Marketing & Medical Innovation at Sysmex Europe where he held various senior management positions for almost ten years. He was also managing director of the Sysmex affiliate, Hitado, which specializes in point-of-care in-vitro diagnostics. Dr Niebald previously worked for Human Diagnostics, Biotrin International and Bayer CropScience AG.
The Abviris co-founders, Dr Ralf Hilfrich and Stefan Raupach, have stepped back from operational responsibilities to take on new advisory roles. Commenting on the company changes, Stefan Raupach said: “With Dr. Roman Niedbal, Abviris has gained an expert with immense expertise and outstanding competence. With his energy and business acumen he will drive the company forward, enabling us to consolidate and expand our innovative solutions, starting with our next generation tumor marker test Prevo-Check®*.”
Dr. Niedbal said: “The Abviris technology offers the potential to improve the quality of life and survival of patients affected by HPV-induced cancers, through early diagnosis and treatment monitoring.
“Our goal is to work with strategic partners to further develop our testing systems, enabling us to bring our products to the worldwide marketplace, and so open up the diagnostic possibilities for patients. As part of this, Abviris is already participating in several multi-center studies designed to demonstrate the clinical benefit of our technology across several disease groups.”
Abviris Germany was founded in 2014 and develops innovative, next-generation products for the early detection and monitoring of HPV-induced tumors. As a potential tool for early detection, its marker test Prevo-Check® adds a new dimension to existing screening programs. Using only a drop of blood or serum, a simple blood test may now be able to detect malignant tumors before any symptoms appear – and deliver results within minutes. For more information see: www.abviris.com
*A multicentre clinical study evaluating this biomarker (DRH1) indicates its diagnostic potential in the early detection of neck, head and anal cancers related to human papilloma viruses (HPV). Results were recently published in Ebiomedicine. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30179-1/fulltext